Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Laughing -- so he had to retract? HAHA. Shoot first, aim later. At least he was man/big enough to correct the obvious mistake. Humble pie doesn't taste good most of the time.
GLTU/A.
I'm surprised they didn't PR the LH initialization (yet).
GLTU/A.
tikotiko - “Hence, the COVID-19 vaccines are not to be treated as commercial products even if issued with an EUA“
I'm not an expert but in the bio realm but definitely hold my own on contracts. I read it as: 'this is strictly government issued, cannot be sold in stores as labeled as 'EUA' for this time'.
Did not take that sentence to be, 'no compensation' at all.
GLTU/A.
Frankly, I was very worried that all our vials would go to the Philippines. Lets think about this logically:
1. In the MSA where I am, there are a majority of LP's, RN's, PA's from the Philippines on the front lines, every day.
2. That talk show interview with Philippine DR and DJ's started a small brush fire. It's getting bigger and it's spreading.
3. As Smiley just mentioned, looks to be the FDA's language is: DON'T WAIT, GRAB WHAT YOU CAN, if not ALL.
CYDY is a business and COVID is what's bringing this company to the forefront this year. If it means to get the best drug available for Severe/Critical patients to our neighboring country so they can continue the pipeline, so be it.
Sad, frustrated, excited at the same time.
We're in a pandemic everyone.. every decision you, or I, a company, or a country makes is likely to be a first in this kind of environment.
Lets rock and roll.
GLTU/A.
SP down, no news is bad news, or results have leaked and are bad.
SP is trending up now, so news has leaked and results are good?
We can use the same logic perhaps?
GLTU/A.
I actually agree with you here JDF. Market is pricing the company where it should be before the unblind. Most longs want this to be at 7-8 handle before lift off.
I'll take 5-6 if not. Lift off is a lift off, nonetheless.
GLTU/A.
Lol - that was pretty funny. Nice one. Agreed it's 'manufactured' in S. Korea but devised in the good Ol U S of A.
GLTU/A.
misiu143 - Firstly welcome back. Secondly, they hit this interview out of the park. This will definitely draw a ton of attention ASAP.
GLTU/A.
pablok - good to hear from the other side. Keep them coming, albeit it daily for now.
GLTU/A.
$.02 above today's low. Good call E.Rabbit. Appreciate your posts. +1.
GLTU/A.
Great time to put your money where you mouth is and short CYDY no?
GLTU/A.
Congrats to those who were able to partake at $6.70. Was looking to add but shorts and weak hands didn't bring it down far enough!
GLTU/A.
Saw your other post. Welcome to the CYDY family. Glad you timed your entry, you have/will make history for you and your family.
A ton of things in the pipeline!
GLTU/A.
This is a 1/8th of all time high volume (that crazy day in June had 100+ mm in volume). We're still ways away from what it should be volume-wise and SP wise but we're getting there.
1 day closer to unblind, 1 day closer to Nasdaq.
IMO - cheap, still very cheap dare I say 2/1.
GLTU/A.
ROCK AND ROLL - HOLD and CLOSE AT $7.00+
The gig may be up for the shorts. Ouch.
Now imagine EUA? Ouch * 2.
GLTU/A.
If we can hold and close $7.00 today, $7 will be the new $3 (from nearly a year ago).
Happy with the volume. Tough to T/A an entry but if you bought in, great, if not time it because this is going to rocket ship up.
Once the CD12 data gets unblinded I would not be surprised to see upwards of $12.50+ and that's being conservative.
New investors, do your DD but understand you are literally buying history in the making and a exciting new journey to the next level.
Welcome aboard, you are saving humanity and making $$. Thats a WIN/WIN in most books!
On the near term horizon (appetizer):
1. Nasdaq uplist.
2. Start/Finish of LH trial.
3. EUA from several countries.
4. Finished HIV BLA's to multiple countries.
Longer term (dessert):
1. NASH trial
2. Basket trial
GLTU/A.
Blane, JPG77, Bulldog88 - congrats on holding and being LONG CYDY.
Lets save the world and make $$. Win/win.
GLTU/A.
DiscusDude - at least he wised up. Writing on the wall is clear as ever. Regardless of motive, if he's for CYDY , he's finally made the right move. There are some though that will never (for reasons unbeknownst to logic and science and testimonies and EIND data and etc...) that will never side with CYDY.
Oh well, their loss (and it's a big one this AM!, LAUGHING) and rep.
GLTU/A.
This is just conjecture here and ALL MO BUT, what other APAC country is close the Philippines that has a direct impact on manufacturing? Didn't Nader say he was going to hop on a plan and go somewhere to get ramped up on manufacturing? Seeming he has an EE background would take him to be efficient and methodical to kill 2 birds with one stone. Also, why is there a job posting on supply manager that just so happened to be opened up in the past week?
Hmm, interesting dots to connect here.
GLTU/A.
Enjoy -
K.I.S.S. - best way to go. And not the HM band.
If someone doesn't understand this logic, well..
GLTU/A.
Lets hypothetically assume all you 'reasoned' is true. So basically, the near 1000 patients that have been dosed LL with their results and the open label expansion that was just granted by the FDA for the same drug different disease.. CYDY doesn't know it's dosages and the half life? Basically, stick em and pray? Hmm.
You have 'your' own good reasons, but look at it the other way.
I'm not sure what the recovery possibilities to this one can be. This one will be a tough one to counter. At least education runs rampant on this board which will be well appreciated from both sides.
CD12 - lets rock and roll.
GLTU/A.
Chuckles759 - you literally ruined this for me for posting that official CYDY link. Dammit!
GLTU/A.
"With a half life of 3.7 days there is no chance Cytodyn" -- link or where you see the half life reference? *serious question*
I'm hoping you didn't calculate this yourself..
GLTU/A.
Latane - Was going to look into this, but really appreciate the time savings post. Thank you.
GLTU/A.
I don't disagree with you and your points are valid. Silly? I wouldn't say watching expenses is silly in any business. Period. This point and crying over the NP/SK making millions spilled milk is another reason why I do not 100% agree with your post. I think other posters, NP himself said it the best but to summarize: "If you don't like what you see, move on". Lest your a short, that is.
GLTU/A.
Not sure the point with your post in reference to my post and equation but one thing does stick out to me when reading yours:
"A company that burns 30m a quarter is worried about saving $2k."
Oh yeah they better be worried about saving every penny. This is a pre-rev biotech for crying out loud..
GLTU/A.
kgromax - you post well and if I recall you understand stats.
"On October 20, 2020, following review and recommendation by the Data Safety Monitoring Committee (DSMC) of data from 195 patients, the Company continued the trial without modification to achieve the primary endpoint. The DSMC also requested a second review of the data after 75% (or 293) of the patients were enrolled and completed a 42-day post-enrollment period. The Company has concluded it will be far more time efficient to forego the second interim analysis and to analyze the data on 390 patients and to provide final data to the U.S. Food and Drug Administration, Health Canada, U.K.’s MHRA, and Philippines FDA, as soon as it is available."
If 42 days from 75% of 390 < 28 days from 100% of 390, which side of the equation makes sense?
GLTU/A
JDF - thanks for the link. Wanted to mention the following from the first PR link:
"On October 20, 2020, following review and recommendation by the Data Safety Monitoring Committee (DSMC) of data from 195 patients, the Company continued the trial without modification to achieve the primary endpoint. The DSMC also requested a second review of the data after 75% (or 293) of the patients were enrolled and completed a 42-day post-enrollment period. The Company has concluded it will be far more time efficient to forego the second interim analysis and to analyze the data on 390 patients and to provide final data to the U.S. Food and Drug Administration, Health Canada, U.K.’s MHRA, and Philippines FDA, as soon as it is available."
Next week is the 42 day mark for the 390. DSMC recommended a 42 day guidance at 75%. I wouldn't be surprised we get a PR then. Hang tight Longs, $$ to be made for some and well, unfortunately, $$ to be lost for others.
Lets rock and roll.
GLTU/A.
Didn't realize I would lose respect on an internet board. mod, or not.
"
Saw this on a different board: https://www.nasdaq.com/market-activity/stocks/cydy/real-time
Figured you guys would like it.
GLTU/A.
"
Looks nice IMO of what's to come for CYDY. Again, just MO.
GLTU/A.
Humbleness and humility gets one to go far in life. I see similar traits in NP and the crew over at CYDY and that's just my opinion.
Results are coming, time's on our side.
Saddle up gentlefolks, there's going to be a whirlwind shortly and some are going to reap it.
GLTU/A.
"Considering the amount of BS " this goes both ways buddy. Longs and shorts need to be able take and dish. There's BS on both sides. One needs to discern what is/not, who is/not. After being on the board for close to a year now, it's very very easy to spot.
GLTU/A.
No, definitely not saying that. Just a preview to what/s to come for CYDY.
Does look nice on that Nasdaq background, doesn't it?
GLTU/A.
Saw this on a different board: https://www.nasdaq.com/market-activity/stocks/cydy/real-time
Figured you guys would like it.
GLTU/A.
I think there was a post from an unofficial website (non-CYDY, non-gov) that mentioned the 21st. I recall that as well.
As you can see, it's the 21st and as it wasn't officially PR'ed, that makes anyone mentioning today's date for anything, moot.
GLTU/A.
little_voice: "I will say that everyone makes mistakes and it is better to admit and deliver the real news now then continue to delay and pivot. "
Whether you hold a short position or now, I can agree with the above statement 100%. Own up to any mistakes.
With that being said, no one said anything would be delivered the 21st, officially (link?)
GLTU/A.
kgromax - "Question for the SEC: does she have any financial interest in having the company succeed." -- seriously, wrong board for this question.
GLTU/A.
The unblind results and eventual EUA, I really wonder as to what day they will announce. Is NP as emphatic as he seems on proactive videos to drop 2 bombs with an EUA and a filing for uplist? This year is going to be legend.. wait for it..
GLTU/A.
Shorts won't be happy about this one: https://www.prnewswire.com/news-releases/fda-authorizes-monoclonal-antibodies-for-treatment-of-covid-19-301212201.html
"PALM BEACH, Fla., Jan. 21, 2021 /PRNewswire/ -- Most of the news on advances for Covid-19 tend to focus on vaccines, however treatments are just as important. While vaccines can stop people from contracting Covid and becoming seriously ill, treatments will still be needed for those who already have it. Having an effective treatment would, in essence, make coronavirus a milder disease. If it stopped people who were admitted to hospital from needing ventilation, then there would be less risk of intensive care units in hospitals being overwhelmed. An article in the BBC said that there are three broad approaches being investigated: Antiviral drugs that directly affect the coronavirus's ability to thrive inside the body; Drugs that calm the immune system (severe Covid-19 is caused by patients' immune systems overreacting and damaging the body); and Antibodies that can target the virus, taken from either survivors blood plasma or made in a lab. It is possible that different drugs will work better at different stages - such as antivirals at the beginning and immune drugs in late-stage diseases. Combinations of therapies are also being investigated. Active Companies in the markets today include BetterLife Pharma Inc. (OTCQB: BETRF) (CSE: BETR), COMPASS Pathways plc (NASDAQ: CMPS), MindMed (OTCQB: MMEDF) (NEO: MMED), CytoDyn Inc. (OTCQB: CYDY), Synairgen plc (OTCPK: SYGGF)."
GLTU/A.